BIOLOGICS MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Dominating Region - North America

North America dominates the biologics industry with an estimated market share of 36.2% in 2024, due to strong presence of global pharmaceutical players like AbbVie Inc. and a well-established healthcare infrastructure. Major markets like the U.S. have fostered innovations in biologics through favourable research policies like the 21st Century Cures Act and financial support for R&D activities.

Fastest-Growing Region - Asia Pacific

Asia Pacific region exhibits the fastest growth due to rising healthcare expenditures, growing disease burden, and increasing focus on ensuring access to advanced treatment options. Counties like China and India are emerging as global biopharma hubs leveraging their large generics manufacturing base and a skilled workforce.

Biologics Market Outlook for Key Countries

U.S. FDA Approvals Boost Biologics Industry Growth

The U.S. dominates the biologics market due to increasing adoption of biologic drugs in oncology and immunology. The approval of breakthrough therapies such as gene therapies and monoclonal antibodies propels market growth. In July 2023, the U.S. FDA approved Eli Lilly and Company's antibody for Alzheimer's treatment, marking a major milestone in biologics.

Local Biosimilars Gain Traction in the Biologics Industry in China

The China biologics market is growing rapidly, driven by substantial investments in biopharmaceutical research and development, as well as production. A key trend is the rising shift toward domestic biologic manufacturing. In June 2023, the National Medical Products Administration (NMPA) approved several biosimilars developed locally, representing a major milestone in the country’s biologics industry.

Advanced Therapies Like CAR T-Cell Therapy Drive Demand in Japan

Japan is witnessing rapid growth in biologics, particularly in immune-oncology treatments. The Japanese government’s commitment to promoting advanced therapies, including CAR T-cell therapies, can drive the market growth. In March 2023, Japan’s Ministry of Health approved the first gene-editing biologic for cancer treatment.

Biotech Startups Thrive with Government Backing in India

India is rapidly emerging as a key player in biologics due to its growing biomanufacturing capabilities and cost-effective biosimilars. The Indian government’s support through its Biotechnology Industry Research Assistance Council (BIRAC) is accelerating market growth. In May 2023, India’s BIRAC announced funding for biotech startups focused on biologics.